Search | Clinical Trials Finder

Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
Interventions: amifostine trihydrate, cisplatin, etoposide, radiation therapy; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 4
States / cities: Denver, Colorado • St Louis, Missouri • Chapel Hill, North Carolina + 1 more

Conditions: Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma, Head and Neck Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer, Limited Stage Small Cell Lung Carcinoma, Myelodysplastic Syndrome, Progesterone Receptor Negative, Progressive Disease, Recurrent Carcinoma, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage IIA Pancreatic Cancer, Stage IIA Rectal Cancer, Stage IIB Pancreatic Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage III Colon Cancer, Stage III Esophageal Cancer, Stage III Gastric Cancer, Stage III Non-Small Cell Lung Cancer, Stage III Ovarian Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Skin Melanoma, Stage IIIA Colon Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Rectal Cancer, Stage IIIA Skin Melanoma, Stage IIIB Colon Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Rectal Cancer, Stage IIIB Skin Melanoma, Stage IIIC Colon Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Rectal Cancer, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Bone Sarcoma, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Ovarian Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IV Soft Tissue Sarcoma, Stage IVA Bone Sarcoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Bone Sarcoma, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Triple-Negative Breast Carcinoma
Interventions: Best Practice, Laboratory Biomarker Analysis, Supportive Care, Survey Administration; Other · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Fullerton, California

Conditions: Carcinoma, Non-Small-Cell-Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
Interventions: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13, Modified Medical Research Council, EQ-5D, Center for Epidemiological Studies Depression Scale, Medical Outcomes Study Social Support Survey; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Durvalumab, Placebo, (Osimertinib cohort, single-arm, open-label separate cohort); Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 80
States / cities: Tuscaloosa, Alabama • Chandler, Arizona • Phoenix, Arizona + 71 more

Conditions: Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions: dasatinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non Small Cell Lung Cancer
Interventions: Group 1: Peripherally Located Tumors, Group 2: Peripherally Located Chest Wall Adjacent Tumors, Group 3: Centrally Located Tumors; Radiation
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 2
States / cities: Hines, Illinois • Maywood, Illinois

Conditions: Non-Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: Precision Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 7
States / cities: Birmingham, Alabama • Stuart, Florida • Louisville, Kentucky + 3 more

Conditions: Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer, Limited Stage Small-Cell Lung Cancer
Interventions: Durvalumab, Monalizumab, Carboplatin or Cisplatin, Etoposide; Drug
Lead sponsor: Hirva Mamdani; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 4
States / cities: Indianapolis, Indiana • Iowa City, Iowa • Detroit, Michigan + 1 more

Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
Interventions: filgrastim, amifostine trihydrate, cisplatin, etoposide, paclitaxel, topotecan hydrochloride, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 84
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 51 more

Conditions: Depression, Lung Cancer
Interventions: counseling intervention, screening questionnaire administration, study of socioeconomic and demographic variables, psychosocial assessment and care; Other · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Lexington, Kentucky • New York, New York

Conditions: Cancer
Interventions: therapeutic allogeneic lymphocytes; Biological
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Small Cell Lung Cancer
Interventions: Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI); Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 35
States / cities: Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more

Conditions: Head and Neck Cancer, Lung Cancer
Interventions: Celecoxib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: sargramostim, amifostine trihydrate, cisplatin, cyclophosphamide, etoposide; Biological · Drug
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Non-small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: Jennifer Bell; Other
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 4
States / cities: Atlanta, Georgia • St Louis, Missouri • Chapel Hill, North Carolina + 1 more

Conditions: Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
Interventions: Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min, Tinostamustine 60mg/m2 over 60min, Tinostamustine 80mg/m2 over 60min, Tinostamustine 100mg/m2 over 60min, Tinostamustine 80mg/m2 over 80min; Drug
Lead sponsor: Mundipharma Research Limited; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 5
States / cities: Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more

Conditions: Lung Cancer
Interventions: questionnaire administration, computed tomography, radiation therapy treatment planning/simulation; Other · Procedure · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Limited-Stage Small Cell Lung Cancer
Interventions: HLX10, carboplatin/cisplatin-etoposide, Thoracic radiotherapy, Placebo, Prophylactic Cranial Irradiation (PCI); Drug · Radiation
Lead sponsor: Shanghai Henlius Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 31
States / cities: Arcadia, California • Los Alamitos, California • Los Angeles, California + 26 more

Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions: Clinical Observation, Crizotinib, Laboratory Biomarker Analysis; Other · Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2036
U.S. locations: 1613
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 978 more

Conditions: Limited Stage Small Cell Lung Cancer
Interventions: Ociperlimab, Tislelizumab, Concurrent Chemoradiotherapy; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Lung Cancer
Interventions: cisplatin, etoposide, tirapazamine, radiation therapy; Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 87
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more

Conditions: Anorexia, Cachexia, Lung Cancer
Interventions: megestrol acetate, radiation therapy; Drug · Radiation
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Breast Cancer, Colorectal Cancer, Lung Cancer, Malignant Mesothelioma, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Thymoma and Thymic Carcinoma
Interventions: educational intervention, psychosocial assessment and care, quality-of-life assessment; Other · Procedure
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-squamous, Non-small Cell Lung Cancer, Squamous
Interventions: PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Hinsdale, Illinois • New Lenox, Illinois

Search by objective public record fields.

Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer

Stereotactic Body Radiation Therapy for Un-biopsied Early- Stage Non Small Cell Lung Cancer

Tissue Collection Study for Patients With Non-Small Cell Lung Cancer With Resectable Disease

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Depression Screening in Patients With Lung Cancer

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer

Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors

Utility of Routine Cervical Mediastinoscopy in Clinical Stage I Non-Small Cell Lung Cancer (NSCLC)

Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer

Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer

Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC